Comparison of the effects of oral dydrogesterone and intramuscular progesterone on the construction of endometrial receptivity

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100042318

Enrollment

Unknown

Registered

2021-01-19

Start date

2021-01-20

Completion date

Unknown

Last updated

2021-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

Interventions

Group 1:In the first cycle, use progesterone intramuscularly, and in the second cycle, use dydrogesterone

Group 2:Dydrogesterone is used in the first cycle, and progesterone is injected intramuscularly in the second cycle

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Aged = 8mm during periovulation; volunteer to join this study.

Exclusion criteria

Exclusion criteria: B ultrasound excluded uneven endometrial echo, endometrial polyps, and adenomyosis; clinically excluded patients with endometriosis r-AFS stage III or higher; clinically excluded hyperprolactinemia and polycystic ovary syndrome, Abnormal thyroid function and autoimmune diseases.

Design outcomes

Primary

Measure	Time frame
Count of pinocytosis and the proportion of various types of pinocytosis, pinocytosis index;	—

Countries

China

Contacts

Public ContactJing Shu

Zhejiang Provincial People's Hospital

shujing@hmc.edu.cn+86 13805705568

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026